Spontaneous Cormophytes from the Romanian Flora Known as Medicinal Plants in Other Countries?

Romania's medicinal flora is an important source of raw material for pharmacological research and drug production. By consulting the pharmacological literature on authenticated scientific sources such as Google Scholar, 15 species of medicinal plants existing in the Romanian flora, but not used in the traditional Romanian medicine, were identified. In accordance with the World Health Organization's call on all countries to use traditional medicine in primary care, we set out to help complete the list of medicinal plants in Romania using information from traditional medicine in other countries.

Risk assessment on drug production safety based on Grey-Analytic Network Process

PurposeTo strengthen the correlation analysis on risk factors of drug production safety and reduce the influence due to fuzzy judgments, a safety risk assessment method based on Grey-Analytic Network Process (G-ANP) is proposed.Design/methodology/approachFirst, an index system evaluating drug production safety risk is constructed according to the “Good Manufacture Practice of Medical Products,” next the influence weight of each risk index is derived by using the Analytic Network Process, then the grey number of each risk index is determined by further utilizing the grey statistical theory, and finally the risk level of drug production is obtained.FindingsAn empirical study is conducted and the results support the feasibility and practicability to use G-ANP method for drug production safety risk evaluation. The results of the case show that it is feasible and practical to use G-ANP method for drug production safety risk evaluation.Originality/valueThe innovation lies in the use of G-ANP method to fully consider the interdependence and interaction between the risk factors of drug production safety, which improves the objectivity in judging the risk level of drug production and provides a scientific basis for pharmaceutical manufacturers to formulate further decisions and management in the case of insufficient quantification of risk factors. Based on the findings, more targeted suggestions are made to reduce the production risk of pharmaceutical enterprises.

Afghan drug production could boom

Significance Anti-drugs rhetoric from senior Taliban figures is intended to allay such concerns, but a sustainable anti-opium strategy would be difficult and destabilising for the Taliban to implement. Impacts The surge in opium prices, noted after the Taliban announced a possible ban, will probably prove fleeting. Methamphetamine production will increase, but is unlikely to displace opium/heroin as Afghanistan’s main illicit export. Climate change will exacerbate drought risks, increasing farmers’ preference for opium over less resilient crops, such as wheat.

Narcotics trafficking will increase in South-east Asia

Significance The ‘Golden Triangle’ -- centred on the tripoint of Laos, Thailand and Myanmar -- has long been a hub for production of illicit drugs. The area is rife with drug cartels. Impacts Regional authorities will continue to make large narcotics seizures but struggle to curb the trade in precursors used in drug manufacture. Laos and Cambodia will find it especially difficult to clamp down on drug trafficking, given their limited resources. Estimating the scale of drug production in Myanmar will get harder as governance in the country weakens.

Blockchain Technology Application as an Add-On Feature in Supply Chain Management of Drug Production Process in the Pharmaceutical Industry

The production process is an important process to determine the quality of drugs produced by the pharmaceutical industry. The production process aims to send goods for use by consumers. This process does not have full visibility and uses a manual process to track the movement of ingredients. This results in a lack of data transparency in drug production, a major problem often faced by the pharmaceutical industry in supply chain management. The process without data transparency will reduce the quality and assurance of drugs and the ability to record information in the drug production process. Based on these problems, this study develops a mobile application by implementing a blockchain system to support the system supply chain management process from material sources, production processes to distribution to consumers. This research was conducted with a prototyping model approach in application development and multichain as blockchain technology. This research produces a mobile application with a blockchain system in the supply chain management process. The development of the application ensures that all transaction data is recorded properly and produces information that anyone can see so that the blockchain system becomes transparent, ensures security, data integrity, and makes tracking production information easier.

NIMble innovation - a networked model for public antibiotic trials

Antibiotic research and development (R&D) is at an inflection point. Faced with ongoing problems with commercial innovation, we argue for a networked public approach to sustainably moving promising compounds through clinical trials. We propose a global public infrastructure of institutes tasked with 1) conducting all trial stages up to market authorization, including small-scale compound production; 2) negotiating licensing agreements for global production and distribution by industry partners; 3) using public purchasing agreements or subscription models to ensure commercially viable drug production at equitable prices. We invite stakeholders to consider our Networked Institute Model’s (NIM) benefits for unblocking the antibiotic pipeline.